公开(公告)号：AU2014295143B2

公开(公告)日：2017-03-16

申请号：AU2014295143

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D417/12

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

公开(公告)号：CA2955570A1

公开(公告)日：2016-02-11

申请号：CA2955570

申请日：2015-08-03

Applicant: BASF SE

Inventor： VIERTELHAUS MARTIN ,  CHIODO TIZIANA ,  SALVADOR BEATE ,  VOSSEN MARCUS ,  HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  WEISHAAR WALTER ,  HELLMANN ROLF

IPC: C07D213/40

Abstract: The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and sol-vents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.

公开(公告)号：AU2014295144A1

公开(公告)日：2016-02-11

申请号：AU2014295144

申请日：2014-07-22

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  BLATTER FRITZ ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  CHIODO TIZIANA ,  HINTERMANN TOBIAS ,  SALVADOR BEATE ,  VOSSEN MARCUS

IPC: C07D417/12 ,  A61K31/506

Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

公开(公告)号：CA2841655A1

公开(公告)日：2013-01-31

申请号：CA2841655

申请日：2012-07-24

Applicant: BASF SE

Inventor： HAFNER ANDREAS ,  HINTERMANN TOBIAS ,  SZELAGIEWICZ MARTIN ,  SIEBENHAAR BERND ,  BLATTER FRITZ

IPC: C07D205/08 ,  C07D207/16

Abstract: Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed.